Argenx's Vyvgart Uptake is Likely to Accelerate, RBC Says

MT Newswires Live

Aug 25

Argenx's (ARGX) Vyvgart, which was launched in 2022, is expected to see an accelerated uptake, RBC said in a Monday research note. Vyvgart is a therapy used to treat severe autoimmune diseases.

Based on its survey, RBC said the uptake might result from higher usage, convenient at-home dosing, lack of any upcoming disruptive competition, and geographical expansion.

RBC analysts expected rest of 2025 to be "relatively light" for Argenx, and said they were "buyers into a very busy 2026-2027 that could potentially more than triple current total addressable market."

The firm initiated its coverage on Argenx with an outperform rating and a $850 price target.

Price: 695.13, Change: +35.13, Percent Change: +5.32

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2562288402"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562288402\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562288402?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-25 22:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562288402","market":"nz","top_or_hot":-1,"title":"Argenx's Vyvgart Uptake is Likely to Accelerate, RBC Says","media":"MT Newswires Live","content":"<html><body><p> Argenx's (ARGX) Vyvgart, which was launched in 2022, is expected to see an accelerated uptake, RBC said in a Monday research note. Vyvgart is a therapy used to treat severe autoimmune diseases.</p><p>Based on its survey, RBC said the uptake might result from higher usage, convenient at-home dosing, lack of any upcoming disruptive competition, and geographical expansion.</p><p>RBC analysts expected rest of 2025 to be \"relatively light\" for Argenx, and said they were \"buyers into a very busy 2026-2027 that could potentially more than triple current total addressable market.\"</p><p>The firm initiated its coverage on Argenx with an outperform rating and a $850 price target.</p><p>Price: 695.13, Change: +35.13, Percent Change: +5.32</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Argenx's Vyvgart Uptake is Likely to Accelerate, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArgenx's Vyvgart Uptake is Likely to Accelerate, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-08-25 22:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Argenx's (ARGX) Vyvgart, which was launched in 2022, is expected to see an accelerated uptake, RBC said in a Monday research note. Vyvgart is a therapy used to treat severe autoimmune diseases.</p><p>Based on its survey, RBC said the uptake might result from higher usage, convenient at-home dosing, lack of any upcoming disruptive competition, and geographical expansion.</p><p>RBC analysts expected rest of 2025 to be \"relatively light\" for Argenx, and said they were \"buyers into a very busy 2026-2027 that could potentially more than triple current total addressable market.\"</p><p>The firm initiated its coverage on Argenx with an outperform rating and a $850 price target.</p><p>Price: 695.13, Change: +35.13, Percent Change: +5.32</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BJT1NW94.SGD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2562288402","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562288402","pubTimestamp":1756132019,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Argenx's  Vyvgart, which was launched in 2022, is expected to see an accelerated uptake, RBC said in a Monday research note. Vyvgart is a therapy used to treat severe autoimmune diseases.Based on its survey, RBC said the uptake might result from higher usage, convenient at-home dosing, lack of any upcoming disruptive competition, and geographical expansion.RBC analysts expected rest of 2025 to be \"relatively light\" for Argenx, and said they were \"buyers into a very busy 2026-2027 that could potentially more than triple current total addressable market.\"The firm initiated its coverage on Argenx with an outperform rating and a $850 price target.Price: 695.13, Change: +35.13, Percent Change: +5.32","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","ARGX":"Argenx SE","AAQC":"Accelerate Acquisition Corp","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4139":"生物科技","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD"},"translate_title":"加拿大皇家银行表示，Argenx对Vyvgart的采用可能会加速","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AAQC":1,"ARGX":0.9},"content_text":"Argenx's (ARGX) Vyvgart, which was launched in 2022, is expected to see an accelerated uptake, RBC said in a Monday research note. Vyvgart is a therapy used to treat severe autoimmune diseases.Based on its survey, RBC said the uptake might result from higher usage, convenient at-home dosing, lack of any upcoming disruptive competition, and geographical expansion.RBC analysts expected rest of 2025 to be \"relatively light\" for Argenx, and said they were \"buyers into a very busy 2026-2027 that could potentially more than triple current total addressable market.\"The firm initiated its coverage on Argenx with an outperform rating and a $850 price target.Price: 695.13, Change: +35.13, Percent Change: +5.32","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}